A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia
Latest Information Update: 07 Mar 2026
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 23 Feb 2026 Planned End Date changed from 1 Jun 2030 to 1 Sep 2029.
- 23 Feb 2026 Planned primary completion date changed from 1 Oct 2027 to 1 Nov 2026.
- 28 Nov 2024 Status changed from not yet recruiting to recruiting.